To evaluate the combined impact of the developing glioma and SorLA loss from host cells on the tumor microenvironment, we first assayed the levels of selected cytokines (TNFα, MIP2, CCL5, CXCL1, IL1β, IL2, IL6, and IL10) in the tissue lysates derived from tumor-bearing and tumor-free hemispheres. The gene discussed is IL1B; the disease is glioma.